Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).
Gilead Sciences Inc. expects supply of the potential COVID-19 drug remdesivir to exceed two million courses by year-end, more than double the company’s previous target of 1 million.
Gilead Sciences Inc is developing easier-to-administer versions of the company’s antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals.
Unlisted Covis Pharma B.V. started a late-stage U.S. randomized trial of the company’s asthma drug Alvesco in non-hospitalized patients with symptomatic COVID-19, hoping the inhaled drug treats symptoms and limits viral replication.
Deaf-owned software company Wavio announced a strategic partnership with AREA 23, an FCB Health Network Company, which includes a major investment deal for the development and product launch of “See Sound.” Created by AREA 23 and Wavio, the revolutionary home device is scheduled to launch during 2020. The partnership provides the FCB Health Network with company equity in Wavio and revenue share on product sales.
Physician-patient engagement has changed rapidly and significantly during the COVID-19 pandemic, with remote conferencing and digital communications becoming increasingly important, according to a new survey of 500 U.S physicians by health and wellness marketing agency AbelsonTaylor.
Origin, a 3D printing specialist for medical devices, completed clinical trials and validation of the company’s 3D-printed nasopharyngeal swabs for use in COVID-19 test kits.
How is COVID-19 impacting physicians’ practices and what does that mean for your business? Join AbelsonTaylor and Veeva Systems for a webinar to explore findings from a survey of 500 physicians in 9 different specialties about the impact of COVID-19.
A new weapon in the war on coronavirus is on the way. Leading health creative agency The Bloc developed SafeCode, a unique device concept which fuses a barcode scanner with UV-C light technology proven to destroy dangerous viruses and bacteria, and is expected to do the same to SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19).
Thermo Fisher Scientific inked a deal with Janssen Biotech, part of Johnson & Johnson, to co-develop a companion diagnostic for cancer. The diagnostic test will support global clinical trial enrollment.